Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal

Pharmacotherapy

Volumn 31, Issue 6, 2011, Pages 566-573

  Martin, Spencer T ^a   Roberts, Keri L ^a   Malek, Sayeed K ^a   Tullius, Stefan G ^a   Vadivel, Nidyanandh ^a,b   De Serres, Sacha ^a,b   Grafals, Monica ^c,d   Elsanjak, Abdelaziz ^a   Filkins, Beth Anne ^a   Chandraker, Anil ^a,b   Gabardi, Steven ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Basiliximab; Early steroid withdrawal; ESW; Induction therapy; Kidney transplantation; r ATG; Rabbit antithymocyte globulin

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BK VIREMIA; BONE MARROW SUPPRESSION; CADAVER KIDNEY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVING DONOR; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE CARE; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; VIREMIA;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; BIOPSY; COHORT STUDIES; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RABBITS; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79957606092     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.6.566     Document Type: Article

References (23)

1. Pascual J, Quereda C, Zamora J, Hernandez D. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Transplant Proc 2005;37:3746-8. (Pubitemid 43015153)
2. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression: a 5-year experience. Am J Transplant 2005;5:2473-8.
3. Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001;72(12 suppl):S72-80.
4. Matas AJ. Minimization of steroids in kidney transplantation. Transpl Int 2009;23:636-40.
5. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008;8:307-16.
6. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008;248:564-77.
7. Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC, for the TRIMS Study Investigators. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with thymoglobulin in living-donor kidney transplantation. Clin Transplant 2010;24:73-83.
8. Heilman RL, Reddy KS, Mazur MJ, et al. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc 2006;38:1307-13.
9. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007;7:1359-75.
10. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002;2:48-56.
11. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004;78:584-90. (Pubitemid 39097106)
12. Haririan A, Morawski K, Sillix DH, et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 2005;79:716-21. (Pubitemid 40463179)
13. Laftavi MR, Stephan R, Stefanick B, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005;137:364-71. (Pubitemid 40312216)
14. Pelletier RP, Akin B, Ferguson RM. Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine. Clin Transplant 2006;20:10-18. (Pubitemid 43349018)
15. Stevens RB, Mercer DF, Grant WJ, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation 2008;85:1391-9.
16. Matas AJ, Ramcharan T, Paraskevas S, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001;1:278-83. (Pubitemid 33674172)
17. Kumar MS, Xiao SG, Fyfe B, et al. Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant 2005;19:61-9. (Pubitemid 40227854)
18. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003;3:306-11. (Pubitemid 36407049)
19. Teraoka S, Sato S, Kai K, et al. Early steroid withdrawal protocol using basiliximab in kidney transplantation. Transplant Proc 2004;36:S478-82.
20. Teraoka S, Sato S, Sekijima M, et al. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid. Transplant Proc 2005;37:791-4. (Pubitemid 40590702)
21. Lebranchu Y, Bridoux F, Büchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002;2:48-56.
22. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004;78:584-90. (Pubitemid 39097106)
23. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-77. (Pubitemid 44708016)